



## Intellia Therapeutics to Present at 2016 Webbush PacGrow Healthcare Conference

August 10, 2016

CAMBRIDGE, Mass., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that CEO and Founder Nessian Bermingham, Ph.D., will present at the 2016 Webbush PacGrow Healthcare Conference.

Details of the presentation are as follows:

### 2016 Webbush PacGrow Healthcare Conference

Date: Wednesday, August 17<sup>th</sup>

Location: Le Parker Meridien, New York

Presentation Time: 10:55 AM EST

Individuals may access a live webcast of the presentation on the Intellia website at [www.intelliatx.com](http://www.intelliatx.com) under "Upcoming Events" in the "Events & Presentations" section. A replay of the webcast will be available on this site for 90 days following the live event.

### About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia was named as one of the top 10 biotech start-ups by *Nature Biotechnology*. In September 2015, Intellia was named a "Fierce 15" biotech company by *FierceBiotech*. Learn more about Intellia Therapeutics and CRISPR/Cas9 at [intelliatx.com](http://intelliatx.com); Follow us on Twitter @intelliatweets.

Media Contact:

Jennifer Mound Smoter  
Chief External Affairs & Communications Officer  
+1 224-804-4462  
[jenn.smoter@intelliatx.com](mailto:jenn.smoter@intelliatx.com)

Investor Contacts:

John Graziano  
Trout Group  
+1 646-378-2942  
[jgraziano@troutgroup.com](mailto:jgraziano@troutgroup.com)

Chad Rubin  
Trout Group  
+1 646-378-2947  
[crubin@troutgroup.com](mailto:crubin@troutgroup.com)



Intellia Therapeutics, Inc.